Publications

Isaacson SH, Ceresoli-Borroni G, Espay AJ et al. International Parkinson and Movement Disorder Society, 2023.

Happel, Grall M, Formella A. World Parkinson Congress 2023, 2023.

Isaacson SH, Grall MS, Gupta F. World Parkinson Congress 2023, 2023.

Farmer J, Goas CJ, Rivera, et al. World Parkinson Congress 2023, 2023.

WangZ, Gomeni R, Hauser R et al. ATMRD, 2023.

Faraone SV, Gomeni R, Hull JT et al. Brain Behav 2023;Feb 27;e2910, 2023.

ATMRD, 2023.

Kosheleff AR, Mason O, Jain R et al. Journal of Attention Disorders 2023:27:669, 2023.

Isaacson SH, Ceresoli-Borroni G, Espay AJ et al. ATMRD, 2023.

Wang Z, Kosheleff AR, Adeojo LW et al. Eur J Drug Metab Pharmacokinet 2022;47:69, 2022.

Nasser A, Gomeni R, Wang Z et al. Br J Clin Pharmacol 2022;88:4828, 2022.

Nasser A, Hull JT, Chaturvedi SA et al. CNS Drugs 2022;36:897-915, 2022.

Faraone SV, Gomeni R, Hull JT et al. Psychiatry Res 2022;318:114922, 2022.

Nasser A, Kosheleff AR, Hull JT et al. Int J Clin Pract 2021;75:e14330, 2021.

Nasser A, Liranso T, Adewole T et al. J Clin Psychopharmacol 2021;41:370, 2021.

Nasser A, Hull JT, Liranso T et al. Neuropsychiatr Dis Treat 2021;17:1751, 2021.

Faraone SV, Gomeni R, Hull JT et al. Paediatr Drugs 2021;23:583, 2021.

Faraone SV, Gomeni R, Hull JT et al. Eur Child Adolesc Psychiatry 2021;https://doi.org/10.1007/s00787-021-01877-5, 2021.

S. Faraone, Gomeni R, Hull JT et al. Psychiatry Research January 2021; 296:113664, 2021.

Nasser A, Liranso T, Adewole T et al. Psychopharmacol Bull 2021;51:43, 2021.

Nasser A, Kosheleff AR, Hull JT et al. Journal Of Child And Adolescent Psychopharmacology, 2021.

Nasser A, Liranso T, Adewole T et al. Clinical Therapeutics, 2021.

Wang Z, Kosheleff AR, Adeojo LW et al. Clinical Pharmacology in Drug Development 2021, 00(0) 1–1, 2021.

Nasser A, Gomeni R, Wang Z, et al. J Clin Pharmacol 2021;61:1626-1637, vol. 61(12), 2021.

Findling RL, Candler SA, Nasser AF et al. CNS Drugs 2021;35:643, 2021.

Nasser A, Hull, Chowdhry F et al. American Professional Society of ADHD and Related Disorders 2020 Annual Meeting, 2020.

Nasser A, Liranso T, Adewole T et al. Clinical Therapeutics 2020;42:1452-1466, 2020.

Yu C, Garcia-Olivares J, Candler S et al. J Exp Pharmacol 2020;12:285-300, 2020.

Nasser A, Faison SL, Liranso T et al. Journal of Clinical Psychiatry;81:20m13395, 2020.

Faison SL, Fry N, Adewole T et al. Clinical Drug Investigation 2020, 2020.

Yu C. Xenobiotica 2020;50:1285, 2020.

Structural Elucidation of the Major Human Metabolites of Viloxazine (poster), 2019.

Johnson JK, Liranso T, Saylor K et al. J Atten Disord 2019;24:348, 2019.

A Double-Blind, Placebo-Controlled, Dose-Ranging Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD (Poster).

Yu C, Garcia-Olivares J, Yegla B et al . Viloxazine Induces Dose-Dependent Increases in Interstitial Levels of Norepinephrine, Dopamine, and Serotonin in Rat Medial Prefrontal Cortex (poster).

Hull JT, Chaturvedi SA, Rubin J, Nasser A. The Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function Assessed via the BRIEF-A in an Open-Label Extension Safety Trial of Adults with Attention-Deficit/Hyperactivity Disorder (poster).

Childress A, Hayman K, Asubonteng K et al. Viloxazine ER (Qelbree®) Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Topline Results of a Phase IV Safety Trial (poster).

Cutler AJ, Childress A, Adler LA et al. Qelbree® (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults with Attention-Deficit/Hyperactivity Disorder (poster).

Faraone SV, Gomeni R, Earnest J, Rubin J. Efficacy of viloxazine ER in treating defiant/aggressive and risky decision-making behaviors in children and adolescents with ADHD (poster).

Earnest J, Hull JT, Koch J et al. Assessment of Pediatric Weight and Height Trajectories During Long-term Viloxazine ER (Qelbree®) Treatment: Interim Results from an Open-label Extension Trial in ADHD (poster).

Cutler A, Childress A, Formella A et al. Qelbree® (Viloxazine ER) Efficacy in Adults with ADHD Inattentive or Combined Presentations (poster).

Garcia-Olivares J, Yegla B, Earnest J et al. Characterization of Viloxazine’s Serotonergic Effects at Doses Relevant for ADHD Treatment (poster).

Garcia-Olivares J, Yegla B, Earnest J et al. Assessment of Serotonergic Effects of Viloxazine in Cynomolgus Monkeys Using PET Imaging with the [11C]CIMBI-36 Serotonin Receptor (5-HT2A/2C) Agonist Radioligand (poster).

Publications

Publication Search Directions

Publications

HCP/FDM Confirmation